Regarding the BI components, insulin degludec has a longer duration of action and a flatter pharmacodynamic profile over the 24 h as compared with IGla‐10064 and is associated with a lower risk for nocturnal hypoglycaemia.65 The gene discussed is INS; the disease is Hypoglycemia.